Bio equivalence study of Tablet Imatinib Mesylate 400 mg in adult patients with Chronic Myeloid Leukemia and /or Gastrointestinal Stromal Tumor who are on stable dose of Tablet Imatinib Mesylate 400 mg under fed condition.
- Conditions
- Health Condition 1: null- Chronic Myeloid Leukemia and or Gastrointestinal Stromal Tumor
- Registration Number
- CTRI/2017/08/009356
- Lead Sponsor
- atco Pharma Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
1.Men and women, of age in between 18 years to 65 years (both inclusive).
2.Ability to provide written informed consent prior to participation in the study.
3.Chronic phase Chronic Myeloid Leukemia (CML) patients with documented evidence of Philadelphia positive chromosome who are on stable dose regimen of 400 mg once daily dose of Imatinib.
And/Or
Kit (CD 117) positive Gastrointestinal Stromal Tumor (GIST) (with documented evidence), who are on a stable dose regimen of 400 mg once daily dose of Imatinib.
4.Adequate organ function, defined as the following:
Hemoglobin > 9 mg/dL
Total bilirubin < 1.5 x upper limit of normal (ULN)
SGOT and SGPT < 2.5 x ULN
Serum Creatinine < 1.5 x ULN
Absolute neutrophil count (ANC) >=1.5 x 109/L
Platelets >= 100 x 109/L
HbA1c < 9 %
5.Females of child-bearing potential (FOCP) must have negative pregnancy test at screening and must agree to use an acceptable method of birth control such as sexual abstinence or at least 2 reliable modes of contraception, one of which must be a double-barrier method (e.g., condom with spermicidal gel or diaphragm with spermicidal gel) or IUD or vaginal spermicidal suppository from screening until 14 days after last dose of study drug. [Note: Use of hormonal contraception (pills/hormonal intrauterine device etc,) is not allowed.] Patient agrees to accept the risk that pregnancy could still result despite using birth control devices.
OR
Post-menopausal females defined as 12 consecutive months of amenorrhea.
OR
Surgically sterilized females with documented evidence of hysterectomy / bilateral salpingectomy / bilateral oophorectomy. Females without documented evidence of surgery and those who has undergone tubal ligation will be considered of child bearing potential.
6.Male patient must agree to use an acceptable method of birth control such as sexual abstinence or barrier method of contraception (i.e. condom) from screening until 14 days after last dose of study drug. Patient agrees to accept the risk that pregnancy in female partner could still result despite using birth control devices.
7.No history of participation in any clinical study within the past 90 days.
1.Patients in accelerated phase or blast crisis phase.
2.Patients for whom a titration away from 400 mg dose is likely during the entire study period as per Investigatorâ??s judgement.
3.Patient received any treatment for CML prior to study entry for longer than 2 weeks with the exception of hydroxyurea and/or anagrelide and/or imatinib.
4.History of patient with another primary malignancy except if the other primary malignancy is neither currently clinically significant or requiring active intervention.
5.Patient having history of major surgery within 4 weeks prior to study entry, or who have not recovered from prior major surgery.
6.Patients with an ECOG (Eastern Cooperative Oncology group) Performance Status Score > 3.
7.Patients with any significant history of non-compliance to medical regimens or with inability to grant a reliable informed consent.
8.Patients with identified sibling donors where allogeneic bone marrow transplant is elected as first line treatment.
9.Patients who are on or may require concomitant medications which are known to be inhibitors and/or inducers of CYP3A4 family (Annexure IV).
10.History of hematopoietic stem cell transplantation.
11.History of hypersensitivity to Imatinib or any of its excipients or related group of drugs.
12.Patients who are eligible and willing to undergo transplantation during the entire study period.
13.History of patients taking certain medications that are accepted to have a risk of causing Torsades de Pointes.
14.History of patients taking medications that irreversibly inhibit platelet function or anticoagulants.
15.History of uncontrolled diseases, such as thyroidal dysfunction, diabetes mellitus, angina pectoris, heart failure, neuropsychiatric disorders.
16.Patients who are at clinically high risk of developing Tumor Lysis Syndrome as per the investigatorâ??s evaluation.
17.Patients who have undergone thyroidectomy or patients receiving levothyroxine.
18.Patients with history of bullous dermatologic reactions, including erythema multiforme and Stevens-Johnson syndrome during the prior therapy with imatinib or any other drug.
19.Recent history (within 6 months) of alcohol and/or drug addiction.
20.Patients who are human immunodeficiency virus (HIV) and HbsAg positive.
21.History of ascites and rapid weight gain with or without superficial edema.
22.History of prior radiotherapy to bone marrow.
23.Use of other concurrent anticancer agents other than Imatinib, including chemotherapy or biologic agents.
24.Positive results for drugs of abuse (benzodiazepines, opioids, amphetamines, cannabinoids cocaine and barbiturates) in urine.
25.Positive results for alcohol as detected by Alcohol Breath Analyzer.
26.History of difficulty with donating blood or difficulty in accessibility of veins.
27.An unusual or abnormal diet, for whatever reason e.g. religious fasting.
28.High caffeine (more than 5 cups of coffee or tea/day) or tobacco (more than 9 cigarettes/ beedies/ cigars per day) consumption.
29.History of patient for whom oral administration of drug is not possible.
30.Any other condition or abnormal baseline findings that, in the investigatorâ??s judgment, might increase the risk to the patient or decrease the chance of obtaining satisfactory data ne
Study & Design
- Study Type
- BA/BE
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method